Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-05
2011-07-05
Fetteroff, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000
Reexamination Certificate
active
07973058
ABSTRACT:
Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
REFERENCES:
patent: 4822802 (1989-04-01), Levy et al.
patent: 4927408 (1990-05-01), Haak et al.
patent: 5207752 (1993-05-01), Sorenson et al.
patent: 5358483 (1994-10-01), Sibalis
patent: 5458569 (1995-10-01), Kirk, III et al.
patent: 5466217 (1995-11-01), Myers et al.
patent: 5533971 (1996-07-01), Phipps
patent: 5605536 (1997-02-01), Sibalis
patent: 5651768 (1997-07-01), Sibalis
patent: 5685837 (1997-11-01), Horstmann et al.
patent: 5697896 (1997-12-01), McNichols et al.
patent: 5807571 (1998-09-01), List et al.
patent: 5882677 (1999-03-01), Kupperblatt
patent: 5941843 (1999-08-01), Atanasoska et al.
patent: 6035234 (2000-03-01), Riddle et al.
patent: 6090095 (2000-07-01), McNichols et al.
patent: 6171294 (2001-01-01), Southam et al.
patent: 6216033 (2001-04-01), Southam et al.
patent: 6245347 (2001-06-01), Zhang et al.
patent: 6421561 (2002-07-01), Morris
patent: 6425892 (2002-07-01), Southam et al.
patent: 6653014 (2003-11-01), Anderson et al.
patent: 6745071 (2004-06-01), Anderson et al.
patent: 6842640 (2005-01-01), Riddle et al.
patent: 6975902 (2005-12-01), Phipps et al.
patent: 7018370 (2006-03-01), Southam et al.
patent: 7302293 (2007-11-01), Southam et al.
patent: 2003/0013753 (2003-01-01), Aung-Din
patent: 2003/0124179 (2003-07-01), Jacobsen et al.
patent: 2004/0242770 (2004-12-01), Feldstein et al.
patent: 2005/0148996 (2005-07-01), Sun et al.
patent: 2005/0228336 (2005-10-01), Keusch et al.
patent: 2006/0253061 (2006-11-01), Anderson et al.
patent: 2007/0093788 (2007-04-01), Carter
Kalia et al (AAPSJ Abstracts, available Apr. 29, 2004).
Fouchard et al (J Controlled Release 49:89-94, 1997).
Femenia-Font et al (Eur J Pharmaceut and Biopharmaceut 61:50-55, 2005).
Christensen, Michael L. et al., “Pharmacokinetics of Sumatriptan Nasal Spray in Adolescents,”J. Clin. Pharmacol., vol. 43:721-726 (2003).
Pierce, M. et al., “NP101: A novel Formulation of Sumatriptan Succinate Utilizing SmartRelief™ Transdermal Technology,”50th Annual Scientific Meeting, American Headache Society, p. S46, No. S17 (2008).
Anderson, Carter R. et al., “Effects of Iontophoresis Current Magnitude and Duration of Dexamethasone Deposition and Localized Drug Retention,”Physical Therapy, vol. 83:161-170 (2003).
Anderson, Carter R. et al., “Quantification of Total Dexamethasone Phosphate Delivery by Iontophoresis,”International Journal of Pharmaceutical Compounding, vol. 7(2):155-159 (2003).
Chaturvedula, Ayyappa et al., “Dermal, Subdermal, and Systemic Concentrations of Granisetron by Iontophoretic Delivery,”Pharmaceutical Research, vol. 22(8):1313-1319 (2005).
Chaturvedula, Ayyappa et al., “In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin,”International Journal of Pharmaceutics, vol. 297:190-196 (2005).
Duquesnoy, C. et al., “Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration,”European Journal of Pharmaceutical Sciences, vol. 6:99-104 (1998).
Jhee, Stanford S. et al., “Pharmacokinetics and Pharmacokynamics of the Triptan Antimigraine Agents,”Clin. Pharmacokinet., vol. 40(3):189-205 (2001).
Lattin, Gary A. et al., “Electronic Control of Iontophoretic Drug Delivery,”Annals of the New Yorker Academy of Sciences, vol. 618:450-464 (1991).
Scholpp, J. et al., “Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan,”Cephalalgia, vol. 24:925-933 (2004).
Xu, Xiaohui et al., “Determination of degradation products of sumatriptan succinate using LC-MS and LC-MS-MS,”Journal of Pharmaceutical and Biomedical Analysis, vol. 26:367-377 (2001).
Alza Corporation (JNJ) Receives FDA Approval for IONSYS™ (Fentanyl Iontophoretic Transdermal System), retrievied online at http://www.biospace.com
ews—story.aspx?NewsEntityId=19447&source=news-email (2006).
Banga, Ajay K. et al., “Iontophoretic Delivery of Drugs: Fundamentals, Developments and Biomedical Applications,”Journal of Controlled Release, vol. 7:1-24 (1988).
Femenia-Font, A. et al., “Iontophoretic Transdermal Delivery of Sumatriptan: Effect of Current Density and Ionic Strength,”Journal of PHarmaceutical Sciences, vol. 94(10):2183-2186 (2005).
Jadoul, Anne et al., “Transdermal Permeation of Alniditan by Iontophoresis: In Vitro Optimization and Human Pharmacokinetic Data,”Pharmaceutical Research, vol. 13(9):1348-1353 (1996).
Kalia, Y. et al., “Transdermal iontophoretic delivery of antimigraine therapeutics in vivo,”2004 AAPS Annual Meeting and Exposition, (2004).
Patel, Sonal R. et al., “In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate,”European Journal of Pharmaceutics and Biopharmaceutics, vol. 66:296-301 (2007).
Patel, Sonal R. et al., “Transdermal iontophoresis of sumatriptan succinate in vitro,”205th Meeting, The Electrochemical Society, Inc., Abs. 725 (2004).
Patel, S.R. et al., “Transdermal iontophoretic delivery of sumatriptan in vitro,” Cephalalgia, Abstracts of the 15th Migraine Trust International Symposium, (2004).
Siegel, Steven J. et al., “A Unique Iontophoretic Patch for Optimal Transdermal Delivery of Sumatriptan,”Pharmaceutical Research, vol. 24(10):1919-1926 (2007).
Vyteris Announces Positive Results for Phase I Clinical Trial,Vyteris Holdings(Nevada),Inc. (2005).
Vyteris, “The smart patch by vyteris, The future of drug delivery . . . today!” JP Morgan 25th Annual Healthcare Conference (Jan. 2007).
International Search Report and Written Opinion for No. PCT/US07/09000.
Anderson Carter R.
Morris Russell L.
Sebree Terri B.
Fetteroff Brandon J
McCarter & English LLP
NuPathe, Inc.
Ricci Craig
LandOfFree
Transdermal methods and systems for the delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdermal methods and systems for the delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal methods and systems for the delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665987